Get Help Sign In


IDT advances human health and clinical research

Mar 26, 2014

Two new xGen® next generation sequencing panels to launch

CORALVILLE, IA – 24 March 2014– Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, is extending its portfolio of NGS panels with the addition of the xGen® Inherited Diseases Panel and the Pan-Cancer Panel. Joining the xGen AML Panel which launched at the end of last year, IDT now offers multiple panels for deep sequencing.

The xGen Inherited Diseases panel will officially launch at the ACMG Annual Clinical Genetics Event, March 26-28. Designed in collaboration with Emory Genetics Laboratory, this panel was created to combine the ease of whole exome sequencing with the low cost of panels. Emory leveraged IDT Lockdown probes to create a library targeting all exons in HGMD (human gene mutation database) listed genes. The creation of this library simplifies workflow and lowers costs, while facilitating rapid sequencing and providing the high coverage levels needed for clinical diagnostic application of NGS. During ACMG Emory will present a poster entitled, ‘One library, many tests: The evolution of Next Generation Sequencing panel testing’.

Launching at AACR, April 5-9, the xGen Pan-Cancer Panel has been developed based on the findings of TCGA (The Cancer Genome Atlas) network. NGS has enabled the discovery and characterization of gene-specific mutations that have the potential to be tumorogenic, but it also implicates irrelevant genes. A shortlist of significant genes that have been deemed relevant across numerous cancer types, which can be expanded through the inclusion of additional tumor-specific genes, would be extremely valuable to both clinical and research applications. TGCA network have identified 127 significantly mutated genes across 12 tumor types. The Pan-Cancer Panel has been designed to target coding regions in all 127 genes.

Target enrichment enables users to focus their sequencing efforts on specific regions of the genome, providing a cost-effective and reliable alternative to whole genome sequencing, making NGS more accessible. Ibrahim Jivanjee, Product Manager for NGS at IDT, commented, “Having launched our xGen AML Panel last October, we have invested a significant amount of time and resource into the further development of our NGS capabilities. As a rapidly advancing area, next gen sequencing is key to the development of personalized medicine, and these two new panels will aid us in supporting the developing advancements in human health and clinical research.”

All three of the IDT NGS Panels use xGen Lockdown® Probes, which are 120mer oligonucleotides with a 5’ biotin modification. Synthesized individually using the IDT Ultramer® synthesis platform, the Lockdown Probes incorporate the highest coupling rate currently available, 99.6%, to provide high quality, long oligos. The quality of each capture probe is assessed using electrospray ionization mass spectrometry and even probes with a high GC content can be synthesized.

Follow us on twitter @idtdna for real-time updates and insights.

Editors’ notes

About IDT

Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the world, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, Calif.; Leuven, Belgium; and Singapore. For more information visit

Integrated DNA Technologies
800-328-2661 (US & Canada)
+1 319-626-8400 (outside US)


Learn about IDT's role in the fight against COVID-19

Media and PR

For media inquiries please contact IDT Public Relations,